Casdin Capital MXCT Position
ExitedCasdin Capital exited their position in MAXCYTE, INC. (MXCT) in Q4 2023, after holding the stock for 4 quarters.
The position was first reported in Q1 2023 and has been tracked across 4 quarterly 13F filings.
1 other tracked fund also holds MXCT.
About MAXCYTE, INC.
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
Full company profile →Short Interest
5.2%
4.7 days to cover
Casdin Capital MXCT Position History
Frequently Asked Questions
Does Casdin Capital own MXCT?
No. Casdin Capital exited their position in MAXCYTE, INC. (MXCT) in Q4 2023. They previously held the stock for 4 quarters.
How many hedge funds own MXCT?
1 specialist biotech hedge fund currently holds MXCT, including Deerfield Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Casdin Capital first buy MXCT?
Casdin Capital's position in MXCT was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Casdin Capital's MXCT position increasing or decreasing?
Casdin Capital completely exited their MXCT position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
MXCTCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Casdin CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →